ADVFN ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P 500
6,263.70
0.32%
US Tech 100
22,266.40
-0.01%
Dow Jones
44,254.78
0.53%
Brent Oil
68.38
0.35%
Bitcoin
119,017.98
0.25%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. TuHURA Biosciences Inc (HURA) Quote

TuHURA Biosciences Inc

TuHURA Biosciences Inc (HURA)

Global X Uranium Index ETF
2.36
0.06
(2.61%)
Closed July 16 4:00PM
15 min delayed - Upgrade to Realtime
2.34
-0.02
(-0.85%)
After Hours: 7:58PM
15 min delayed - Upgrade to Realtime

TuHURA Biosciences Inc (HURA) Quote

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
2.34
( 1.74% )
Bid
2.30
Ask
2.34
Volume
229,844
2.23 Day's Range 2.38
1.80 52 Week Range 7.93
Market Cap
102.212M
Previous Close
2.30
Open
2.29
Last Trade
200
@
2.34
(formt)
Last Trade Time
Financial Volume
$ 525,995
VWAP
2.2885
Average Volume (3m)
241,392
Shares Outstanding
43,680,396
Dividend Yield
-
PE Ratio
-4.55
Earnings Per Share (EPS)
-0.52
Revenue
-
Net Profit
-22.65M

About TuHURA Biosciences Inc

TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company's lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It ... TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company's lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first line treatment for advanced Merkel cell carcinoma. In addition, the Company is leveraging its Delta receptor technology to develop novel bi-functional antibody drug conjugates (ADCs), targeting myeloid derived suppressor cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. Its IFx platform technology utilizes a proprietary plasmid DNA (pDNA) or messenger RNA (mRNA). Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.kintara.com
Headquarters
Reno, Nevada, USA
Founded
-
TuHURA Biosciences Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker HURA. The last closing price for TuHURA Biosciences was $2.30. Over the last year, TuHURA Biosciences shares have traded in a share price range of $ 1.80 to $ 7.93.

TuHURA Biosciences currently has 43,680,396 shares outstanding. The market capitalization of TuHURA Biosciences is $100.46 million. TuHURA Biosciences has a price to earnings ratio (PE ratio) of -4.55.

Ask ADVFN Intelligence (AI)

HURA Latest News

More News

Form 8-K - Current report
Edgar (US Regulatory)
June 30 2025
HURA (2.61%)

Form D - Notice of Exempt Offering of Securities
Edgar (US Regulatory)
June 13 2025
HURA (2.61%)

Form 8-K - Current report
Edgar (US Regulatory)
June 12 2025
HURA (2.61%)

Form 8-K - Current report
Edgar (US Regulatory)
June 06 2025
HURA (2.61%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.14-5.645161290322.482.552.261821072.38844685CS
4-0.06-2.52.42.772.15207602.37773338CS
12-1.86-44.28571428574.24.32.12413922.72712103CS
26-2.35-50.10660980814.695.271.82312743.22082007CS
52-4.21-64.27480916036.557.931.82576904.00862653CS
156-4.21-64.27480916036.557.931.82576904.00862653CS
260-4.21-64.27480916036.557.931.82576904.00862653CS

HURA - Frequently Asked Questions (FAQ)

What is the current TuHURA Biosciences share price?
The current share price of TuHURA Biosciences is $ 2.34
How many TuHURA Biosciences shares are in issue?
TuHURA Biosciences has 43,680,396 shares in issue
What is the market cap of TuHURA Biosciences?
The market capitalisation of TuHURA Biosciences is USD 100.46M
What is the 1 year trading range for TuHURA Biosciences share price?
TuHURA Biosciences has traded in the range of $ 1.80 to $ 7.93 during the past year
What is the PE ratio of TuHURA Biosciences?
The price to earnings ratio of TuHURA Biosciences is -4.55
What is the reporting currency for TuHURA Biosciences?
TuHURA Biosciences reports financial results in USD
What is the latest annual profit for TuHURA Biosciences?
The latest annual profit of TuHURA Biosciences is USD -22.65M
What is the registered address of TuHURA Biosciences?
The registered address for TuHURA Biosciences is 50 WEST LIBERTY STREET, SUITE 880, RENO, NEVADA, 89501
What is the TuHURA Biosciences website address?
The website address for TuHURA Biosciences is www.kintara.com
Which industry sector does TuHURA Biosciences operate in?
TuHURA Biosciences operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
YHCLQR House Inc
$ 10.76
(172.41%)
49.7M
NUWENewellis Inc
$ 15.94
(131.18%)
40.03M
APMAptorum Group Ltd
$ 1.93
(99.01%)
196.41M
RGTXDefiance Daily Target 2X Long RGTI ETF
$ 56.25
(60.49%)
3.24M
DTSTData Storage Corporation
$ 5.2952
(56.66%)
14.95M
ZVSAZyVersa Therapeutics Inc
$ 0.31
(-43.53%)
12.45M
CGBSCrown LNG Holdings Ltd
$ 0.03795
(-38.09%)
197.49M
CYCCCyclacel Pharmaceuticals Inc
$ 8.16
(-33.82%)
3.55M
NCPLNetcapital Inc
$ 3.2519
(-28.53%)
2.22M
JUNSJupiter Neurosciences Inc
$ 2.125
(-28.45%)
929.83k
GTIGraphjet Technology
$ 0.102
(39.73%)
452.38M
OPENOpendoor Technologies Inc
$ 1.49
(43.27%)
303.75M
IXHLIncannex Healthcare Ltd
$ 0.3869
(13.79%)
284.94M
CGBSCrown LNG Holdings Ltd
$ 0.03795
(-38.09%)
197.49M
APMAptorum Group Ltd
$ 1.93
(99.01%)
196.41M

Discussion

View Full Feed
e-ore e-ore 3 minutes ago
Straka, Conners, Rose, Schauffele, Fitzpatrick 278

Good luck to all!
Bud Powell Bud Powell 4 minutes ago
yea, I noticed most people have sort of "checked" out, especially in public social interactions
AVXL
seekinganswers seekinganswers 5 minutes ago
"Now that others connected the dots". LOL, what a foolish statement!

There were no dots connected, just more breadcrumbs and random universal dots that have been fantasized about since circa 2015.
The only "dots" to be discussed are;.... the failed phase 3 trial, the failed
NWBO
Art67 Art67 5 minutes ago
this whole thing is positioned for this moment,there's a reason Ken has a coin years ago,,there's a reason why Jeff is Ceo of all people.
WDLF
MiamiGent MiamiGent 7 minutes ago
Yes. I believe so, too. Just another reason we have to get to the bottom of the Epstein matter. We cannot allow any country intentionally compromise our elected leaders.
janice shell janice shell 7 minutes ago
Yes to all that. But Mamdani is genuinely charismatic. That counts for a lot.
CaptHowdy CaptHowdy 7 minutes ago
I'd expect more that a measly 7.5% of the allocated $2M set aside for share buy backs to be utilized. The volume is promising but it hardly moved the SP with sustainable staying power. Bummer.

Tomorrow and Friday we shall see if that volume was frontloading by short sellers or buy bac
NXPL
Cambreau Cambreau 9 minutes ago
Was blessed to be in pvdg in 2021 when it went from trips to .10. Nowadays just getting to .01 would seem like a HR. Maybe this one will be the needle in a haystack ?
PSWW
2can$ 2can$ 9 minutes ago
The otc slayer.


Hello Fung_derf.
Thank you for reaching out to me glad you are well.
Say have you ever had to apologize to another adult for being wrong about something anything as an adult?
DBMM
downdraft downdraft 9 minutes ago
Yep, that’s the coin flip. If the new FDA truly does have the backs of health insurance providers, then stem cell procedures could finally go mainstream, just like how chiropractic went from skeptical to mainstream, decades ago. I believe the stem cell business in the U.S. is finally about to have i
ADIA
BadCuda BadCuda 11 minutes ago
what's the cost to get it out of the ground and process it per oz , I'd estimate about 1000+- just saying 
DTREF
rrojarom rrojarom 12 minutes ago
TAMPA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Full Alliance Group, Inc. (OTC: FAGI) (“the Company”), through its majority-owned subsidiary Qubitera Holdings, proudly announces the launch of the YAHBEE SHOPPING NETWORK — a groundbreaking platform that fuses home shopping, affiliate marketing, and bl
FAGI
surfer44 surfer44 12 minutes ago
MMW 2025: Day 3 – Gas Tankers Panel - How is US Fueled Export Growth Shaping the Gas Tanker Market?

https://youtu.be/EEVF1gBWkFU
blackhawks blackhawks 12 minutes ago
I like them because they are thorough AND nuanced. 'Up in the air', unless and until, IS nuance.

Key points:

Maxwell filed her petition for review in April 2025 after losing her appeal in the Second Circuit.

The DOJ’s reply, filed by the latest deadline o
igotthemojo igotthemojo 13 minutes ago
"In addition, the number of shares traded since 10 Jul don't even come close to 6.7 million shares. Since 10 Jul, about 4.1 million shares have been traded (and that includes today)."

EXACTLY...

"That is why I postulated that the 6.7 million shares might have been eithe
KBLB
bigtalan bigtalan 15 minutes ago
AI
is KRM-ll-81 in tier 3 preclinical or has that conclude for NIH HEAL Initiative
It's difficult to definitively say whether KRM-II-81 is currently in "Tier 3 preclinical" stage or if that stage has concluded within the NIH HEAL Initiative because the tiered system for the Preclinical
RSPI
blackcat blackcat 16 minutes ago
Well- there is this.

Attorney General Pam Bondi’s Justice Department has fired Maurene Comey, who is the daughter of former FBI Director James Comey and the federal prosecutor in the Sean “Diddy” Combs, Jeffrey Epstein and Ghislaine Maxwell cases, according to reports.

stark12 stark12 16 minutes ago
Wasn't thinking of selling at the time just disappointed in management. The candid conversation we had was helpful but nothing subsequently has helped to really right what has been a pattern of delay and lack of transparency. 
NB
PennyMillions852 PennyMillions852 16 minutes ago
Penny first…let’s not jump the gun!
TWOH
janice shell janice shell 16 minutes ago
It's not just Diddy. Maurene Comey was also the prosecutor who tried Epstein and Ghislaine Maxwell.

So why did he want to fire her? I've lost track of what's a "hoax" by now.
236T568 236T568 18 minutes ago
Run Run Run Janice, Run Run Run


LOLOLOLOLISSIMO!! Yes, Annabelle may be more twisted than we thought.

Your Recent History

NASDAQ
HURA
TuHURA Biosciences
Delayed Upgrade Clock
ADVFN
InvestorsHub
United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN Ltd - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads